Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.


Options:
A: Arm Label: 1. Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Basiliximab | Arm Label: 2. 40 mg Simulect; Type: EXPERIMENTAL; Interventions: Drug: Basiliximab | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): 1. Placebo, 2. 40 mg Simulect
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tralokinumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tralokinumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 0.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 10 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 3 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 0.5 mg BID | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 50 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: PBO-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Arm Label: GLM-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 50 mg Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance, GLM-I-Rsp-Golimumab 50 mg Maintenance, GLM-I-nonRsp-Golimumab 100 mg Maintenance, Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, PBO-I-nonRsp-Golimumab 100 mg Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance

Answer: D